ALIM — Alimera Sciences Share News
0.000.00%
Last trade - 00:00- $301.29m
- $360.44m
- $80.75m
Brief: Alimera Sciences Announces 2022 Financial Results And Business Update
Alimera Sciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Alimera Improves Capital Structure, Strengthens Balance Sheet And Extends Term Loan Facility
Brief: Alimera Sciences - Does Not Hold Cash Deposits Or Securities With SVB Or Signature
Brief: Alimera Announces Submission Of Marketing Authorization Application In Switzerland For ILUVIEN
Alimera Sciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Alimera Sciences Appoints Russell Skibsted As Chief Financial Officer
Brief: Alimera Sciences To Extend Interest-Only Period On Loan Agreement With SLR Investment
Brief: Alimera Sciences Announces Q3 Financial Results
Alimera Sciences Inc reports results for the quarter ended in September - Earnings Summary
Alimera Sciences Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Alimera Sciences To Report Third Quarter 2022 Financial Results On Monday, November 14, 2022, And Provide Corporate Update
Alimera Sciences Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Paladin Phase 4 Study Confirms Iluvien® Patients' Reduced Need For Multiple Treatments
Brief: Alimera Announces Reimbursement Of Uveitis Indication Granted For Iluvien In Ireland
Brief: Alimera Announces Reimbursement Of Uveitis Indication Granted For Iluvien In Portugal
Alimera Sciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Alimera Sciences Announces Second Quarter 2022 Financial Results
Brief: Paladin Phase 4 Study Confirms Safety Of Durable Iluvien Treatment And Reduces Burden Of Care For DME Patients